Patent ID: 8067434
Filing Date: 2011-11-29
Classification: A61P,C07D

Abstract:
1. A method for treating a patient suffering from or at risk of a RET-mediated condition selected from the group consisting of multiple endocrine neoplasia, type IIA (MEN2A), multiple endocrine neoplasia, type JIB (MEN2B), medullary thyroid carcinoma (MTC), familial medullary thyroid carcinomas (FMTC), and papillary thyroid carcinomas (PTC) for which Ret modulation provides a therapeutic benefit, said method comprising administering to said patient a Ret modulator having a chemical structure of Formula I, or a prodrug or pharmaceutically acceptable salt thereof, wherein: R R R R R R R X=O or S; and n=0, 1, or 2.